BC Extra | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

MD Anderson, Takeda partner for CAR NK cell therapies  The University of Texas MD Anderson Cancer Center partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to develop and commercialize up to four allogeneic CAR NK...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 16, 2018
Clinical News

Pfizer launches U.S.’s first biosimilar epoetin

Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen and Johnson...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
BC Week In Review | May 18, 2018
Clinical News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
BC Week In Review | May 18, 2018
Clinical News

FDA approves Pfizer's Retacrit, first epoetin alfa biosimilar in U.S.

FDA approved Retacrit epoetin alfa-epbx from Pfizer Inc. (NYSE:PFE), a biosimilar of anemia drugs Epogen from Amgen Inc. (NASDAQ:AMGN) and Procrit from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ). FDA said it...
BC Extra | May 16, 2018
Company News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BC Week In Review | Mar 30, 2018
Clinical News

FDA panel backs US WorldMeds' opioid withdrawal candidate

US WorldMeds LLC (Louisville, Ky.) said FDA's Psychopharmacologic Drugs Advisory Committee voted 11-1 to recommend approval of an NDA for lofexidine to reduce symptoms associated with opioid withdrawal and facilitation of completion of opioid discontinuation...
BC Week In Review | Mar 9, 2018
Clinical News

FDA panel to review US WorldMeds' opioid withdrawal candidate

FDA said its Psychopharmacologic Drugs Advisory Committee will meet on March 27 to discuss an NDA from US WorldMeds LLC (Lousiville, Ky.) for lofexidine to reduce symptoms associated with opioid withdrawal and facilitation of completion...
Items per page:
1 - 10 of 71
BC Extra | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

MD Anderson, Takeda partner for CAR NK cell therapies  The University of Texas MD Anderson Cancer Center partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to develop and commercialize up to four allogeneic CAR NK...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 16, 2018
Clinical News

Pfizer launches U.S.’s first biosimilar epoetin

Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen and Johnson...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
BC Week In Review | May 18, 2018
Clinical News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
BC Week In Review | May 18, 2018
Clinical News

FDA approves Pfizer's Retacrit, first epoetin alfa biosimilar in U.S.

FDA approved Retacrit epoetin alfa-epbx from Pfizer Inc. (NYSE:PFE), a biosimilar of anemia drugs Epogen from Amgen Inc. (NASDAQ:AMGN) and Procrit from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ). FDA said it...
BC Extra | May 16, 2018
Company News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BC Week In Review | Mar 30, 2018
Clinical News

FDA panel backs US WorldMeds' opioid withdrawal candidate

US WorldMeds LLC (Louisville, Ky.) said FDA's Psychopharmacologic Drugs Advisory Committee voted 11-1 to recommend approval of an NDA for lofexidine to reduce symptoms associated with opioid withdrawal and facilitation of completion of opioid discontinuation...
BC Week In Review | Mar 9, 2018
Clinical News

FDA panel to review US WorldMeds' opioid withdrawal candidate

FDA said its Psychopharmacologic Drugs Advisory Committee will meet on March 27 to discuss an NDA from US WorldMeds LLC (Lousiville, Ky.) for lofexidine to reduce symptoms associated with opioid withdrawal and facilitation of completion...
Items per page:
1 - 10 of 71